Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06963216 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
A Phase 3 study of Acquired Factor X Deficiency, sponsored by Kedrion S.p.A..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT06963216 is a Phase 3 study of Acquired Factor X Deficiency that is actively recruiting participants, run by Kedrion S.p.A.. The registered enrollment target is 15 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06963216, a Phase 3 study of Acquired Factor X Deficiency, is actively recruiting participants, sponsored by Kedrion S.p.A..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
Conditions Studied
Interventions
- BIOLOGICAL Coagadex(R)
Study Locations (3)
Arizona
- Mayo Clinic Arizona - Phoenix
Minnesota
- Mayo Clinic Rochester - Rochester
London
- Cancer Clinical Trials Unit - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06963216
The ClinicalTrials.gov registry entry for NCT06963216 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kedrion S.p.A., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acquired Factor X Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Coagadex(R) is the first listed.
NCT06963216 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Minnesota, London.
Frequently Asked Questions
What is clinical trial NCT06963216 about?
NCT06963216 is a clinical study titled "A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis". The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
What is the current status of trial NCT06963216?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2026-02. Estimated completion is 2027-09.
What conditions does trial NCT06963216 study?
This clinical trial studies the following conditions: Acquired Factor X Deficiency.
What interventions are being tested in trial NCT06963216?
The interventions under investigation include: Coagadex(R) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06963216?
This trial is sponsored by Kedrion S.p.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06963216 being conducted?
This trial has 3 study locations across Arizona, Minnesota, London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.